2-(1H-4(5)-imidazoyl) cyclopropyl compounds

PCT No. PCT/US96/07833 Sec. 371 Date Feb. 6, 1998 Sec. 102(e) Date Feb. 6, 1998 PCT Filed May 29, 1996 PCT Pub. No. WO96/38141 PCT Pub. Date Dec. 5, 1996The present invention provides compounds having H3 histamine receptor antagonist activity of formula (1.0) wherein R2 is a hydrogen or a methyl or...

Full description

Saved in:
Bibliographic Details
Main Authors TEDFORD; CLARK E, PHILLIPS; JAMES G, KHAN; AMIN MOHAMMED
Format Patent
LanguageEnglish
Published 23.11.1999
Edition6
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:PCT No. PCT/US96/07833 Sec. 371 Date Feb. 6, 1998 Sec. 102(e) Date Feb. 6, 1998 PCT Filed May 29, 1996 PCT Pub. No. WO96/38141 PCT Pub. Date Dec. 5, 1996The present invention provides compounds having H3 histamine receptor antagonist activity of formula (1.0) wherein R2 is a hydrogen or a methyl or ethyl group; R3 is a hydrogen or a methyl or ethyl group; n is 0, 1, 2, 3, 4, 5, or 6; and R1 is selected from the group consisting of (a) C3 to C8 cycloalkyl; (b) phenyl or substituted pneyly; (c) alkyl; (d) heterocyclic; (e) decahydronaphthalene; and (f) octahydroindene; with the proviso that when X is H, A can be -CH2CH2, -COCH2-CON(CH3)-, -CH=CH-, alpha , -CH2-NH-, -CH3-N(CH3)-, -CH(OH)CH2-, -NH-CH2-, -N(CH3)-CH2-, -CH2O-, -CH2S-, and -NHCOO-; when X is NH2, HN(CH3), N(CH3)2, OH, OCH3, CH3, SH and SCH3; A can be -NHCO-, -N(CH3)-CO-, -NHCH2-, -N(CH3)-CH2-, -CH=XH-, -COCH2-, -CH2CH2-, -CH( )H)CH2-, or beta ; and when R1 and X taken together denote a 5,6 or 6,6 saturated bicyclic ring structure, X can be NH, O, or S. The pharmaceutically acceptable salts, hydrates, and individual stereoisomers of compounds of structural formula (1.0), as well as mixtures thereof, are also contemplated as falling within the scope of the present invention. The invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with an effective amount of a compound of said formula and a method of treating conditions in which antagonism of histamine H3 receptors may be of therapeutic importance.
Bibliography:Application Number: US19980945915